Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 600

1.

The effects of etoposide on testicular function in boys treated for Hodgkin's disease.

Gerres L, Brämswig JH, Schlegel W, Jürgens H, Schellong G.

Cancer. 1998 Nov 15;83(10):2217-22.

PMID:
9827728
2.
3.
4.

[Testicular function after OPA/COMP chemotherapy without procarbazine in boys with Hodgkin's disease. Results in 25 patients of the DAL-HD-85 study].

Hassel JU, Brämswig JH, Schlegel W, Schellong G.

Klin Padiatr. 1991 Jul-Aug;203(4):268-72. German.

PMID:
1942933
5.

[Changes in gonadal function in post-pubertal male survivors of acute lymphoblastic leukemia and Hodgkin's disease].

Soriano Guillén L, Muñoz Calvo MT, Pozo Román J, Contra Gómez T, Buño Soto M, Argente Oliver J.

An Esp Pediatr. 2000 Oct;53(4):318-23. Spanish.

PMID:
11083980
6.

Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study.

Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D.

J Clin Oncol. 2010 Aug 10;28(23):3680-6. doi: 10.1200/JCO.2009.26.9381. Epub 2010 Jul 12.

PMID:
20625128
7.

Gonadal function following ABVD therapy for Hodgkin's disease.

Kulkarni SS, Sastry PS, Saikia TK, Parikh PM, Gopal R, Advani SH.

Am J Clin Oncol. 1997 Aug;20(4):354-7.

PMID:
9256888
8.

Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.

Dieckmann K, Pötter R, Hofmann J, Heinzl H, Wagner W, Schellong G; Pediatric Cooperative Hodgkin Disease Study Group of the GPOH..

Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):644-52.

PMID:
12788169
9.

Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook.

Dörffel W, Lüders H, Rühl U, Albrecht M, Marciniak H, Parwaresch R, Pötter R, Schellong G, Schwarze EW, Wickmann L.

Klin Padiatr. 2003 May-Jun;215(3):139-45.

PMID:
12838937
10.

Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma.

Bokemeyer C, Schmoll HJ, van Rhee J, Kuczyk M, Schuppert F, Poliwoda H.

Ann Hematol. 1994 Mar;68(3):105-10.

PMID:
8167175
11.

Gonadal function in young patients successfully treated for Hodgkin disease.

Papadakis V, Vlachopapadopoulou E, Van Syckle K, Ganshaw L, Kalmanti M, Tan C, Sklar C.

Med Pediatr Oncol. 1999 May;32(5):366-72.

PMID:
10219339
12.

Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin's disease.

Kreuser ED, Xiros N, Hetzel WD, Heimpel H.

J Cancer Res Clin Oncol. 1987;113(3):260-6.

PMID:
3108263
13.

Gonadal function in prepubertal boys following treatment for Hodgkin's disease.

Dhabhar BN, Malhotra H, Joseph R, Garde S, Bhasin S, Sheth A, Advani SH.

Am J Pediatr Hematol Oncol. 1993 Aug;15(3):306-10.

PMID:
8328644
14.

Testicular dysfunction after cyclophosphamide-vincristine-procarbazine-prednisolone chemotherapy for advanced Hodgkin's disease. A long-term follow-up study.

Charak BS, Gupta R, Mandrekar P, Sheth NA, Banavali SD, Saikia TK, Gopal R, Dinshaw KA, Advani SH.

Cancer. 1990 May 1;65(9):1903-6.

15.

Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group.

Tesch H, Diehl V, Lathan B, Hasenclever D, Sieber M, Rüffer U, Engert A, Franklin J, Pfreundschuh M, Schalk KP, Schwieder G, Wulf G, Dölken G, Worst P, Koch P, Schmitz N, Bruntsch U, Tirier C, Müller U, Loeffler M.

Blood. 1998 Dec 15;92(12):4560-7.

16.

Decreased serum inhibin B/FSH ratio as a marker of Sertoli cell function in male survivors after chemotherapy in childhood and adolescence.

Bordallo MA, Guimarães MM, Pessoa CH, Carriço MK, Dimetz T, Gazolla HM, Dobbin J, Castilho IA.

J Pediatr Endocrinol Metab. 2004 Jun;17(6):879-87.

PMID:
15270406
17.

High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group.

Schellong G, Pötter R, Brämswig J, Wagner W, Prott FJ, Dörffel W, Körholz D, Mann G, Rath B, Reiter A, Weissbach G, Riepenhausen M, Thiemann M, Schwarze EW.

J Clin Oncol. 1999 Dec;17(12):3736-44.

PMID:
10577845
18.

[Preliminary results of reproductive system function assessment in young men after Hodgkin's disease therapy].

Moryl-Bujakowska A, Balwierz W, Małek A, Sztefko K.

Przegl Lek. 2010;67(6):382-6. Polish.

PMID:
21344766
19.

Irreversible gonadal damage in male survivors of pediatric Hodgkin's disease.

Heikens J, Behrendt H, Adriaanse R, Berghout A.

Cancer. 1996 Nov 1;78(9):2020-4.

20.

Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.

Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E.

Cancer. 2000 May 1;88(9):2142-8.

PMID:
10813727

Supplemental Content

Support Center